Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Beactica, a Swedish drug discovery company, has signed a new research collaboration agreement with GE Healthcare, a provider of molecular interaction analysis tools, and Uppsala University, Sweden.
Subscribe to our email newsletter
The collaboration combines Beactica’s unique approach to fragment-based drug discovery and GE Healthcare’s Biacore technology with enzymology expertise from Uppsala University, said Beactica.
Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore surface plasmon resonance instruments and applications for fragment-based drug discovery. The project also aims to identify novel high-quality leads against a clinically important, undisclosed protein target from Beactica’s discovery pipeline. Financial terms of the agreement were not disclosed.
Per Kallblad, CEO of Beactica, said: “We look forward to deepening our relationship with GE Healthcare and Uppsala University. The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next-generation applications from GE Healthcare will enable us to stay at the forefront of our field.”